Digital gamma camera developer Digirad of San Diego announced this month that it has signed a distribution and service agreement with National Imaging Resources for its Digirad 2020 TC Imager. Birmingham, AL-based NIR will gain U.S. distribution rights
Digital gamma camera developer Digirad of San Diego announced this month that it has signed a distribution and service agreement with National Imaging Resources for its Digirad 2020 TC Imager. Birmingham, AL-based NIR will gain U.S. distribution rights to the system, which uses solid-state detectors made from cadmium zinc telluride.
The agreement gives Digirad access to a strong sales structure it has not had before: NIR boasts 190 sales representatives, a 400-member service organization, and a regional network consisting of more than 50 locations. But NIR also expects to benefit from the deal, gaining access to the nuclear medicine market. NIR reports annual sales of more than $500 million.
The deal further strengthens Digirad's market position, especially in light of patents the company received last month that cover a method of manufacturing solid-state digital detector modules (SCAN 10/28/98). Digirad 2020 TC Imager was cleared by the Food and Drug Administration in June 1997 (SCAN 6/11/97).
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.